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ABSTRACT
OBJECTIVE: To analyze the trends and factors associated with the 
antidepressant use among older adults.
METHODS: This population-based study evaluated older adults in 
1997 (n = 351, baseline) and the survivors at the 15th follow-up year 
(n = 462, in 2012) among the aging cohort of Bambuí. The prevalence of 
antidepressant use was estimated, and the most commonly used antidepressants 
each year were identified. Prevalence ratios with 95% confidence intervals 
were estimated using Poisson regression with robust variance to investigate 
differences in the prevalence of use between 1997 and 2012.
RESULTS: The overall consumption of antidepressants (PR = 2.87, 
95%CI 1.94;4.25) and of selective serotonin reuptake inhibitors (PR = 7.50, 
95%CI 3.74;15.02) was significantly higher in 2012. However, no significant 
difference was observed in the use of tricyclic antidepressants between 
the two cohorts (PR = 0.89, 95%CI 0.49;1.62). In the 2012 cohort, 
antidepressant use was associated with females, increased age, increased 
income (≥ 4 minimum wages), self-assessment of health as reasonable, and 
attending ≥ 5 medical consultations in the last 12 months.
CONCLUSIONS: The increased consumption of antidepressants in the 
period due to increased use of selective serotonin reuptake inhibitors 
was consistent with results observed in international studies of different 
population groups and contexts. The positive correlation observed between 
antidepressant use and family income may be a warning of possible 
inequalities in access to mental health services.
DESCRIPTORS: Aged. Antidepressive Agents, therapeutic use. Drug 
Utilization, trends. Socioeconomic Factors. Pharmacoepidemiology.
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Antidepressants (AD) are considered the treatment of 
choice in acute manifestations of moderate to severe 
depression for improvement or complete remission 
of symptoms.9 AD are also used in the management 
of other health problems, including anxiety disorders 
and chronic pain.15
International population-based studies have identified 
growth in AD use, both in the general adult popula-
tion2,17 and among older adults.8,12 This growth is due 
to greater use of selective serotonin reuptake inhibitors, 
which are gradually replacing tricyclic AD as the most 
commonly used chemical subgroup.2,13,17
To date, only one Brazilian study20 has evaluated the 
trends in AD consumption among different population 
groups. It was conducted in a mid-sized city in Southern 
Brazil, and it evaluated the use of psychotropic drugs in 
the adult population aged ≥ 15 years between 1994 and 
RESUMO
OBJETIVO: Analisar a tendência e os fatores associados ao uso de 
antidepressivos por idosos mais velhos.
MÉTODOS: Estudo de base populacional com idosos integrantes da linha 
base (n = 351, em 1997) e dos sobreviventes no 15º seguimento (n = 462, em 
2012) da coorte idosa de Bambuí. Estimou-se a prevalência do consumo de 
antidepressivos e foram identificados os antidepressivos mais consumidos 
em cada ano. Razões de prevalência com intervalos de confiança de 95% 
foram estimadas por meio da regressão de Poisson, com variância robusta, 
na investigação de diferenças de prevalência no uso do medicamento entre 
os dois anos.
RESULTADOS: O consumo global de antidepressivo (RP = 2,87; 
IC95% 1,94;4,25) e do grupo dos inibidores seletivos da recaptura da 
serotonina (RP = 7,50; IC95% 3,74;15,02) foi significativamente maior em 
2012. Entretanto, não foi observada diferença significativa no consumo de 
antidepressivos tricíclicos entre as duas coortes (RP = 0,89; IC95% 0,49;1,62). 
Na coorte recente (2012), o uso de antidepressivos mostrou-se associado ao 
sexo feminino, à idade e à renda (≥ 4 salários mínimos) mais elevadas, à 
autoavaliação da saúde como razoável e à realização de cinco ou mais consultas 
médicas nos últimos 12 meses.
CONCLUSÕES: O crescimento do consumo de antidepressivos no período, 
devido ao aumento no uso dos inibidores seletivos da recaptura da serotonina, 
mostrou-se consistente com o observado em estudos internacionais, com 
diferentes populações e contextos. A associação positiva observada em relação à 
renda alerta para possível desigualdade no acesso aos serviços de saúde mental.
DESCRITORES: Idoso. Antidepressivos, uso terapêutico. Uso 
de Medicamentos, tendências. Fatores Socioeconômicos. 
Farmacoepidemiologia.
INTRODUCTION
2003. The authors reported a significant increase from 
8.4% to 31.6% in AD use. However, this difference was 
not adjusted for sample characteristics that could be 
associated with the consumption of AD. Other Brazilian 
studies have investigated AD use at the population level 
in terms of prevalence and associated factors. However, 
they evaluated the overall adult population.6,10,19
The presence of chronic comorbidities is a common 
condition among older adults, and depression is among 
the chronic diseases that often affects this population.5 
Older adults are the main consumers of AD6,20,23 and 
consumption among older adults is higher than that 
in their younger counterparts.3 Considering the rapid 
aging of the Brazilian population, the challenges this 
phenomenon poses to pharmaceutical care, and the lim-
ited number of studies on this topic, this study aimed to 
evaluate the trend and factors associated with AD use 
among older adults.
859Rev Saúde Pública 2014;48(6):857-865
METHODS
This study is a substudy of the Bambuí Project, a longi-
tudinal study investigating the incidence and predictors 
of health outcomes among older adults in a community 
living situation. Details of the methodology used have 
been presented in a previous publication.16
The aforementioned study16 was conducted in the city 
of Bambuí, located in Southwestern state of Minas 
Gerais, with 15,000 inhabitants in 1997, when the base-
line cohort was evaluated by a census of older adults 
living in the city. In the present study, the older adults 
considered eligible to participate were aged between 
75 and 89 years who were among the baseline of the 
1997 cohort (born between 1908 and 1922), herein des-
ignated the 1997 cohort, and the survivors of this same 
cohort in 2012, herein designated the 2012 cohort, in 
the same age group (born between 1923 and 1937).
The dependent variable was AD use reported by par-
ticipants in interviews when the drug label and medi-
cal prescription were also examined. The medications 
were identified and their active principles were classi-
fied according to the Anatomical Therapeutic Chemical 
Indexa (ATC).
The medications listed in ATC under code N06A were 
considered AD. In addition, AD were classified accord-
ing to their chemical subgroup (ATC level 4) and chemi-
cal substance (ATC level 5).
The independent variables included sociodemographic 
characteristics, health conditions, and descriptors of the 
use of health care services. Sociodemographic character-
istics included sex, age, education (none, 1-3, and ≥ 4 full 
years), marital status (married/consensual union, widowed, 
divorced/single), family income (< 2.0, 2.0-3.9, and ≥ 
4.0 minimum wage equivalents), and living status (liv-
ing alone, not living alone). The minimum wage was 
equivalent to US$120.00 in 1997 and US$333.00 in 
2012. The health conditions investigated included the 
presence of common mental disorders (depression and 
anxiety), self-assessment of health, number of chronic 
diseases, and functional disability. The common mental 
disorders were evaluated using the 12-item version of 
the General Health Questionnaire (GHQ-12),11 and indi-
viduals with scores ≥ 5 points were considered positive. 
Self-assessment of health was based on the answer to 
the question: “How would you rate your health?” (very 
good/good; reasonable; poor). The chronic health con-
ditions evaluated were hypertension, diabetes, Chagas 
disease, heart attack, and stroke, and they were measured 
on the basis of the patients’ medical diagnostic reports. 
With regard to functional capacity, older adults were 
considered functionally disabled if they experienced 
difficulty or were unable to perform at least one of the 
following basic activities of daily living without help: 
getting out of bed, eating, walking from one room to 
another, and bathing. Hospitalization history, number 
of medical consultations over the past 12 months, and 
health insurance coverage were the descriptor variables 
related to the use of health care services.
Data were collected in the homes using questionnaires 
administered by the interviewers. Interviewers were 
recruited from the community, had education superior 
to 11 years, and were trained by the research team, 
ensuring consistency in applying the instruments and 
collecting the data in 1997 and 2012.
The prevalence of AD use (overall and by chemical sub-
group) was calculated separately for each birth cohort 
by dividing the number of older adults reporting AD 
consumption by the total number of cohort members. 
In the evaluation of the chemical subgroups and most 
commonly used active ingredients, the medication was 
considered the unit of analysis. Therefore, the ratios 
were calculated by dividing the total number of AD in 
each chemical subgroup or active principle by the total 
number of AD reported. The chemical subgroups consid-
ered were selective serotonin reuptake inhibitors (SSRI), 
tricyclic AD (TCA), and monoamine oxidase inhibitors 
(MAOI). The Chi-square test was used to compare the 
two birth cohorts in relation to the variables evaluated. 
The factors associated with AD use (global) in each birth 
cohort were evaluated using Poisson regression with 
robust variance to estimate the prevalence ratios and 
95% confidence intervals. The inclusion of a covari-
ate in the statistical model was not influenced by the 
results of the univariate analyses. The same analytical 
strategy was used to test the hypothesis of association 
between the year of the cohort and AD use (overall and 
by chemical subgroup). However, to determine the dif-
ferences in the prevalence of use between the 1997 and 
the 2012 cohorts, only the variables independently asso-
ciated with AD use in at least one of the cohorts were 
included in the multivariate model. In all analytical steps, 
a significance level of 5% was used. Data analysis was 
performed using Stata® version 10 statistical software 
(Stata Corp., College Station, USA).
The Bambuí Project was approved by the Research 
Ethics Committee of the René Rachou Research Center 
(Opinion 346,329 – CAAE 01082212.7.0000.5091). 
All participants from both cohorts signed a free and 
informed consent form.
RESULTS
The 1997 cohort (n = 351) and the 2012 cohort 
(n = 462) were similar in age (means of 79.8 and 79.9 years, 
a World Health Organization. Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2013. Geneva; 2013. Available from: 
http://www.whocc.no/atc_ddd_index
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respectively), sex (60.1% and 66.5% were females, 
respectively), and marital status (50.4% and 57.7% 
were widowed, respectively). When compared with 
the 1997 cohort, the 2012 cohort had higher education 
and income (p < 0.001 for both variables), lower preva-
lence of depressive disorders, less disability for at least 
one basic activity of daily living, better self-assessment 
of health (p < 0.001), better health insurance coverage 
(p < 0.001), and higher frequency of medical consulta-
tions in the past 12 months (p = 0.014), although mem-
bers of this cohort were hospitalized less during in the 
same period (p = 0.048). The complete characterization 
of the two cohorts can be observed in Table 1.
AD use increased from 8.3% in 1997 to 23.6% in 2012, 
and this trend was observed in both sexes and in all 
age groups. In both cohorts, consumption was higher 
among females and increased with age, except among 
the older male adults of the 1997 cohort, whose con-
sumption was stable across the age groups (Figure).
With regards to the pharmacological classes, changes 
in the consumption pattern were observed between the 
two cohorts; the consumption of TCA prevailed in the 
1997 cohort, accounting for 69.0% of total AD con-
sumption, whereas the consumption of SSRI prevailed 
in the 2012 cohort, accounting for 68.1% of total AD 
consumption. The use of MAOI was observed only in 
the 1997 cohort and the use of other AD (code N06AX) 
was restricted to the 2012 cohort. However, in both 
cohorts, the consumption of these chemical groups was 
lower than that of TCA and SSRI. Citalopram was the 
most frequently used active ingredient, corresponding to 
31.1% of total consumption in the 2012 cohort, whereas 
no active ingredient predominated in the 1997 cohort 
(data not shown).
In the 2012 cohort, the following factors were posi-
tively associated (p < 0.05) with AD use after uni-
variate analysis: female sex, age, and family income 
(among the sociodemographic characteristics), pres-
ence of depressive disorders, self-assessment of health 
as poor (among the health conditions), having two or 
more medical consultations, and type of health insur-
ance coverage (among the characteristics pertaining 
to the use of health care services). The following vari-
ables were positively associated with AD use after 
multivariate analysis: female sex, family income ≥ 4 
minimum wage equivalents, self-assessment of health 
as reasonable, and having five or more medical con-
sultations in the last 12 months (Table 2). In the 1997 
cohort, having five or more medical consultations was 
the only variable positively associated with AD use 
using both univariate and multivariate analyses (OR = 
4.41, 95%CI 1.21;16.1) (data not shown).
Table 3 shows the results of univariate and multivariate 
analyses for the association between birth cohorts and 
AD use (overall and for the two most commonly used 
chemical subgroups). Even after adjusting for sex, age, 
family income, self-assessment of health, and number of 
medical consultations, the overall consumption of AD 
and SSRI was significantly higher in the 2012 cohort. 
However, no significant difference was observed in 
the consumption of TCA between the two cohorts. 
Considering that AD use differed between older males 
and females, a trend analysis was conducted to evaluate 
medication use stratified by sex. However, the results 
obtained within each stratum did not differ from those 
observed in the total population.
DISCUSSION
This study identified a significant increase in AD use 
between 1997 and 2012, primarily due to increased con-
sumption of SSRI. In both cohorts and in all age groups, 
consumption of AD was higher among females. In the 
2012 cohort, in addition to females, increased age and 
income, self-assessment of health as reasonable, and 
attending five or more medical consultations in the past 
12 months were positively associated with AD use.
Between 1997 and 2012, the consumption of AD by older 
adults from Bambuí significantly increased approximately 
three fold, regardless of the characteristics associated 
with their use in this cohort. Growth in the consump-
tion of AD has also been observed in higher-income 
countries among the general adult2,17 and older adult 
population.4,8,12,13 A Brazilian population-based study 
showed a significant increase in AD use from 8.4% to 
31.6% but included not only the older groups but all 
residents aged ≥ 15 years.20
Previous studies have elucidated the reasons for the 
growing AD use, and these reasons are not mutually 
exclusive. The most obvious reason is the increased 
prevalence of depression in the older population.1 In 
fact, in addition to improved diagnosis of depressive 
disorders by healthcare professionals,2,20 depression 
in the final stage of life is a common event among 
older adults owing to the presence of chronic dis-
eases, impaired functional capacity, loneliness, and 
decreased social support network.1,13 Another cause 
would be extended drug treatment for depression, 
particularly among those with a history of multiple 
depressive episodes. This has also been observed 
in international studies, whether based on primary 
data14,21,22 or on databases of consultations and medi-
cal prescriptions.18 A third cause is growing accep-
tance among healthcare professionals and patients of 
the new generation of AD such as SSRI, which have 
fewer side effects and are better tolerated and safer 
than TCA and MAOI (older class), particularly in 
overdose situations.14 The fact that depressive older 
adults are commonly treated with drugs at the expense 
of other therapeutic options, such as psychotherapy, 
also should not be discarded.24
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Table 1. Comparison of the profile of the 1997 cohort (baseline) and survivors (2012 cohort) in Bambuí, state of Minas Gerais, 
Southeastern Brazil.
Variable 1997 (N = 351) 2012 (N = 462) p
Age in yearsa 79.8 (3.7) 79.9 (3.8)  0.712
Sex
Male 39.9 33.6
Female 60.1 66.5 0.063
Education (years completed)
0 39.0 24.7
1 to 3 29.6 36.6
≥ 4 31.4 38.7 < 0.001
Marital status
Married/Consensual union 36.5 33.4
Widowed 50.4 57.7
Single or divorced 13.1  8.9  0.056
Family income (in minimum wage equivalents)
< 2.0 35.1 20.9
2.0 to 3.9 34.3 44.6
≥ 4.0 30.6 34.6  < 0.001
Lives alone
No 80.1 73.3
Yes 19.9 26.7  0.025
Depressive disorders
No 57.2 80.7
Yes 42.8 19.3 < 0.001
Self-assessment of health
Very good/Good 31.9 53.5
Reasonable 45.9 37.5
Poor 22.2  9.1 < 0.001
Number of chronic diseases
0 35.0 14.2
1 43.0 46.4
≥ 2 22.0 39.4 < 0.001
Inability to perform at least one basic activity of daily living
No 75.6 85.0
Yes 24.4 15.0  0.001
Number of medical consultations in the last 12 months
0 to 1 33.1 23.8
2 to 4 40.2 46.3
≥ 5 26.8 29.9  0.014
Hospitalization history in the past 12 months
No 71.8 77.9
Yes 28.2 22.2  0.048
Health insurance coverage
No 82.6 66.6
Yes 17.4 34.4 < 0.001
a Mean (SD).
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In line with the results of international population-based 
studies,2,17,25 the increased consumption of AD in Bambuí 
was primarily due to the increased use of SSRI, consid-
ering that the consumption of TCA was similar between 
the two cohorts. The prevalence of SSRI among AD 
used by the 2012 cohort is consistent with that observed 
in Brazil6,19 and other countries.22 This result indicates 
the possibility that among the older people of Bambuí, 
increased consumption of AD results from greater accep-
tance of SSRI by professionals and patients. After the 
appearance of this chemical subgroup, general practi-
tioners have more frequently prescribed AD, a practice 
that used to be restricted to psychiatrists.17 It is note-
worthy that only 1.0% of the population consulted a 
psychiatrist. Furthermore, a negative correlation was 
observed between the increased prevalence of AD con-
sumption and depression in the 2012 cohort. This may 
be due to adequate treatment among older adults in the 
2012 cohort, resulting in improvement or remission of 
depressive symptoms and consequently a negative rat-
ing for the GHQ-12. This may also be a consequence 
of AD use in the management of other health problems, 
such as anxiety disorders and other chronic diseases.4
The identification of independent factors associated 
with AD use was largely confined to the 2012 cohort. 
In the 1997 cohort, the only characteristic associated 
with AD use after multiple adjustments was the num-
ber of medical consultations.
The consumption of AD was higher among females. 
International12,14,17,25 and Brazilian studies6,10,19 have shown 
an association between females and AD use. Some authors 
argue that the higher consumption of AD among females 
is due to the increased prevalence of depressive disor-
ders in this group.6,10,17 However, in the present study, 
the association between females and AD use remained 
significant regardless of the presence of depressive dis-
orders. Grunenbaum12 (2008) draws attention to the pos-
sibility of feminization of depression, because females 
identify psychiatric conditions and pursue treatment 
for these disorders more intensely than males. In this 
study, the consumption of AD did not significantly dif-
fer between males and females presenting with depres-
sive disorders, but was significantly different among 
those without depressive disorders (data not shown). 
This result could indicate that, in Bambuí, older females 
use AD to treat health problems other than depression, 
such as anxiety disorders, sleep disturbances, physical 
problems, and even social problems caused by the diffi-
culties experienced in daily life.25 Alternatively, females 
may adhere to the pharmacological treatment of depres-
sion more often than males.
Other sociodemographic characteristics associated with 
AD use were increased age and higher income. A posi-
tive association between age and AD use was observed 
in other older groups.13,25 General practitioners have 
reported depression at the end of life as a spectrum that 
includes loneliness, lack of social network, and impaired 
functionality.13 As for the positive association between 
income and AD use, increased access to medications 
could be due to greater ability to bear health costs among 
those with better socioeconomic status.10 In Bambuí, the 
prevalence of depressive disorders was higher among 
the lower income strata (data not shown), which raises 
concerns about possible inequalities in mental health 
care in this population segment due to its limited access 
to mental health care services.6
In the case of descriptive variables related to health 
conditions and use of health care services, only the 
self-assessment of health (in the first case) and the num-
ber of medical consultations (in the second) were asso-
ciated with AD use after adjusting for other covariables. 
The positive association between consumption of AD 
and worse self-assessment of health (even restricted to 
assessment as “reasonable”) is consistent with results 
observed among older Australian adults25 and indicates 
the importance of subjective assessment of health in 
determining AD use. The positive association between 
consumption of AD and the number of medical consul-
tations is related to the need for a prescription from a 
medical professional in order to obtain the drug.
One limitation of this study is the inability to assess the 
appropriate AD use with regard to drug indication and dos-
age, owing to the lack of use of a gold standard method 
for diagnosing depression as well as the unavailability of 
data on duration of use/dosage for medications and access 
to psychotherapy. The GHQ-1211 screening tool used to 
evaluate common mental disorders in the study popula-
tion showed the same accuracy as the 30-item Geriatric 
Depression Scale (GDS-30) in diagnosing depressive 
symptoms.7 However, the GHQ-12 only verifies the pres-
ence of symptoms of depression and does not define clini-
cal diagnosis. Moreover, the cutoff value used to classify 
the participants as positive did not allow differentiation 
Figure. Antidepressant use by sex and age among individuals 
aged 75-89 years. Bambuí, MG, Southeastern Brazil, 1997 
and 2012.
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Table 2. Results of univariate and multivariate analyses of factors associated with antidepressant use among individuals aged 
75-89 years. Bambuí, MG, Southeastern Brazil, 2012.
Characteristics % PRraw 95%CI PRadjusted 95%CI
Age 80.7 (4.0)a 1.06 1.01;1.10 1.05 1.01;1.09
Sex 
Male 14.8 1.00 1.00
Female 28.0 1.89 1.24;2.87 1.77 1.11;2.82
Education (years completed)
None 19.3 1.00 1.00
1 to 3 29.4 1.29 0.81;2.04 1.43 0.87;2.35
≥ 4 25.1 1.30 0.83;2.05 1.33 0.78;2.26
Marital status 
Married/Consensual union 19.5 1.00 1.00
Widowed 26.7 1.37 0.94;2.00 1.02 0.66;1.58
Single or divorced 19.5 2.00 0.50;2.02 1.02 0.53;1.97
Family income (in minimum wages) 
< 2.0 18.2 1.00 1.00
2.0 to 3.9 20.0 1.07 0.65;1.76 1.40 0.82;2.39
≥ 4.0 30.2 1.61 1.00;2.60 1.93 1.08;3.45
Lives alone
No 23.0 1.00 1.00
Yes 23.8 1.03 0.71;1.50 1.33 0.82;2.13
Depressive disorders
No 20.9 1.00 1.00
Yes 34.8 1.67 1.18;2.36 1.26 0.86;1.86
Self-assessment of health
Very good/Good 18.2 1.00 1.00
Reasonable 29.5 1.62 1.14;2.30 1.62 1.13;2.32
Poor 31.0 1.70 1.01;2.87 1.50 0.83;2.70
Number of chronic diseases
None 24.6 1.00 1.00
1 24.1 0.98 0.60;1.59 0.80 0.50;1.26
≥ 2 23.3 0.95 0.57;1.57 0.74 0.45;1.22
Inability to perform at least one basic activity of daily living 
No 22.1 1.00 1.00
Yes 31.9 1.45 0.98;2.14 1.01 0.65;1.59
Number of medical consultations 
0 to 1 12.7 1.00 1.00
2 to 4 23.8 1.87 1.09;3.23 1.61 0.92;2.82
≥ 5 31.9 2.51 1.45;4.33 2.10 1.16;3.81
Hospitalization history
No 22.0 1.00 1.00
Yes 27.7 1.26 0.87;1.83 1.07 0.69;1.64
Health insurance coverage 
No 20.0 1.00 1.00
Yes 31.4 1.57 1.13;2.17 1.37 0.95;1.97
Raw and adjusted PR (for all variables described in the table) estimated using Poisson regression model with robust variance.
a Mean (SD).
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between mild or severe symptoms. For the first case, psy-
chotherapy is indicated, whereas drug therapy is the first 
choice in cases of severe depression.9 Another limitation is 
the impossibility of verifying whether AD was prescribed 
by a psychiatrist. The present results cannot be general-
ized to other older groups, particularly those attending 
geriatric day hospitals or nursing homes. However, the 
study has advantages, particularly when compared with 
studies on drug dispensing or those based on prescrip-
tions because it uses data on drug use. In addition, the 
accuracy of the measurements was ensured by the veri-
fication of drug label and prescription. The population-
based strategy adopted, the minimum loss of informa-
tion on the medications used by the eligible participants, 
and uniform procedures for data collection between the 
cohorts ensured the reliability and internal validity of the 
study. Furthermore, to the best of our knowledge, this is 
the first Brazilian population-based study that evaluated 
the trends in AD consumption among older adults.
In summary, the increased consumption of AD and the 
predominance of new generation drugs were consistent 
with findings observed in international studies of different 
populations and experimental designs. The positive associa-
tion observed between AD consumption and income may 
indicate potential inequalities in accessing mental health 
services. Further studies employing different methodolo-
gies and designs (e.g., qualitative and longitudinal epide-
miological studies) are necessary to deepen knowledge 
concerning AD use among older people. Furthermore, 
it can support interventions that will improve access to 
pharmaceutical care services with coverage and quality 
that are adequate for managing health problems of psy-
chological origin in this population segment.
Table 3. Antidepressant use among older adults aged 75-89 years. Bambuí, MG, Southeastern Brazil, 1997 and 2012.
Antidepressant use 1997 2012 PRraw 95%CI PRadjusteda  95%CI
Global (%) 8.3 23.6 2.86 1.94;4.20 2.87 1.94;4.25
Tricyclic compounds (%) 5.7  5.6 0.99 0.56;1.74 0.89 0.49;1.62
Selective serotonin reuptake 
inhibitors (%)
2.3 17.3 7.60 3.62;15.05 7.50 3.74;15.02
Estimation of PR using Poisson regression with robust variance.
a Adjusted for sex, age, family income, self-rated health assessment, and number of medical consultations.
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